Allergy Vaccines

AT's current portfolio of competitive products includes marketed products containing allergoids, (modified allergens) tyrosine depot and MPL® adjuvant. These technologies offer significant benefits over older allergy vaccination technologies. AT's development programme is designed to improve product characteristics e.g. provide an improved safety profile and reduce the number of injections over the treatment period, resulting in well-accepted registered products likely to be prescribed by a higher percentage of physicians.

Read more

Allergy Therapeutics has a long-term commitment to research and in particular development of innovative therapies for both the treatment and prevention of allergy-related conditions. Included in this section are details of our current clinical programme and a selection of our scientific publications.

Of course due to the nature of R&D projects, this information including the status of these products is subject to change at any time.

Our current list of products in development reflects both in-house efforts and collaborations with outside companies and organisations.